Search Media Items

Chordoma is a slow growing cancer of tissue found inside the spine, formed from the left-over cells that were important in the development of the spine before birth. Learn more about chrodomas, how they are diagnosed, and how they are treated.

Adamantinoma is a rare bone cancer, which mostly grows in the lower leg, tough it can apear in the forearm, jaw, hands, or feet. Adamantinoma is a serious condition. Treatment is important for survival, but it is possible to make a full recovery.

Learn about recent findings from studies that used immunotherapy and targeted therapies to treat lung cancer. Find how research efforts to detect lung cancer early are using blood and sputum samples and even artificial intelligence.

The National CryoEM Facility provides cancer researchers access to the latest technology for high resolution imaging. View a list of acknowledged publications from National CryoEM Facility’s users.

Using TCGA in your research? Learn about the data and other resources available.

Read how melanoma survivor T.J. Sharpe’s experience on two clinical trials highlights the need for biomarkers to predict benefit from immunotherapy.

While standard biological methods such as two-dimensional, in vitro cell culture and in vivo animal models are useful to examine certain biological questions, the complexity of cancer requires a continuum of model systems. This collaborative study will create a foundation for tumor tissue engineering by employing multiple innovative methodologies to first characterize and then build biomimetic models of the extracellular matrix (ECM) in the tumor microenvironment. The ECM is a key element in biomimicry, and particularly important to consider in the context of cancer, where the composition and architecture of the ECM change drastically with disease progression.

Learn about the NCI-funded research that enabled the first FDA approved precision medicine- the immune checkpoint inhibitor pembrolizumab.

Read how an NCI-funded team led by Robert Vonderheide showed the promise of combining immune checkpoint inhibitors and radiation therapy in melanoma.

The results of standard tests indicated that Valerie Winston was at risk for multiple myeloma. Read how an NCI combination therapy clinical trial helped her avoid the full impact of multiple myeloma.